Merck ’s MRK stock has declined around 10.3% in the past three months, losing almost $32 billion of its market value.

Merck & Co. said a European Medicines Agency panel recommended expanded approval of the drugmaker's blockbuster cancer treatment Keytruda in two types of gynecologic cancers.

Charlie CY Yang, an analyst from Bank of America Securities, maintained the Buy rating on Merck & Company (MRK – Research Report).

Deep-pocketed investors have adopted a bullish approach towards Merck & Co MRK, and it's something market players shouldn't ...

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

(MRK) said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment for ...

Lack of a skilled talent pool, and slow logistics operations are among the major challenges that could discourage India’s ...

Shares of Intel and Merck are posting strong returns Friday morning, lifting the Dow Jones Industrial Average into positive territory. Shares of Intel and Merck are contributing to the index's ...

While economic data may be scarce, every data point gives a new angle to the ever-uncertain economic conditions in the US.

Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males ...

In the world of pharmaceuticals, companies aim to operate under GMP guidelines — a set of production and manufacturing ...

Health care stocks lagged the S&P 500 in 2023, but they can often be a solid defensive play in an uncertain economy. People don't typically reduce their prescription drug purchases or put ...